Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenalidomide + dexamethasone + donor lymphocyte infusion
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allogeneic iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Oral, Intravenous
01
Overview
Lenalidomide + dexamethasone + donor lymphocyte infusion (DLI) is a combination regimen primarily used in the treatment of multiple myeloma and other hematologic malignancies. Lenalidomide is an immunomodulatory agent that works by enhancing immune function, inhibiting angiogenesis, and inducing apoptosis of malignant cells. Dexamethasone is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive properties; it also induces apoptosis in certain cancer cells and enhances the efficacy of lenalidomide. Donor lymphocyte infusion (DLI) involves the administration of lymphocytes from a stem cell transplant donor to boost graft-versus-tumor effects after allogeneic hematopoietic stem cell transplantation. This combination aims to maximize anti-myeloma activity through direct cytotoxicity (lenalidomide/dexamethasone) and immune-mediated mechanisms (DLI). Lenalidomide was developed by Celgene (now part of Bristol Myers Squibb), while dexamethasone is an older generic drug produced by various manufacturers.
- Other names
- lenalidomidedexamethasoneDLIdonor lymphocyte infusion
02
Targets
GR (Glucocorticoid receptor)CRBN (Cereblon)pMHC–TCR (Peptide–MHC–T-cell receptor complex)
Beyond the preview
Go deeper on lenalidomide + dexamethasone + donor lymphocyte infusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenalidomide + dexamethasone + donor lymphocyte infusion.